• london biotech banner
  • Dermatology June 24 Conference
MedEdge MEA MedEdge_Logo_Dark

Public Relations, Top Health Magazine and Healthcare News GCC

  • Newsletters
  • Magazines
  • Subscribe
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
      • Healthcare Journals & Publishers
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Reading: Breakthrough! New Weapon Strikes Down Breast Cancer Recurrence
Share
Notification
  • london biotech banner
  • Dermatology June 24 Conference
MedEdge MEA
  • Magazines
  • Newsletters
  • Profiles
  • Subscribe
Search
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Have an existing account? Sign In
MedEdge MEA > Health For All > Women and Child Health > Breakthrough! New Weapon Strikes Down Breast Cancer Recurrence
Women and Child HealthLeadLife Style & WellnessNews

Breakthrough! New Weapon Strikes Down Breast Cancer Recurrence

ME Web Desk
Web Desk
Published: June 29, 2024
Share
3 Min Read
Breast Cancer Recurrence
SHARE

June 2024- A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.

In a clinical trial involving 512 patients with the earliest stage of breast cancer that tested positive for the HER2 protein, 97% of those treated with trastuzumab emtansine (T-DM1) after surgery were alive and free of invasive cancer five years after treatment. The results, published online today in the Journal of Clinical Oncology, suggest that T-DM1 is a reasonable treatment approach for this stage 1 population, the study authors say.

Moreover, In conjunction with the trial, researchers looked for biomarkers of whether the cancer was likely to recur even after treatment with T-DM1. They found that patients with high scores on the HER2DX test – which weighs clinical factors and the activity of four genes within tumor tissue – had a greater risk of recurrence.

“Patients with stage 1 HER2-positive breast cancer have recurrence rates of 5 to 30%. Post-surgical treatment with chemotherapy and the antibody trastuzumab, which binds to HER2, can significantly reduce the risk of recurrence in these patients. But the side effects can have a detrimental impact on patients’ quality of life,” says study lead author Paolo Tarantino, MD, of Dana-Farber and the University of Milan (Italy). “In this study, we evaluated T-DM1, which links trastuzumab to a powerful chemotherapy agent, for effectiveness and toxicity in this group of patients.”

Also Read: Ministry of Health and Prevention-UAE Commences “Powered by You” Breast Cancer Awareness Campaign

Researchers enrolled 512 patients at cancer centers across the U.S., treating 384 with T-DM1 and 128 with chemotherapy and trastuzumab. Investigators found that, five years after treatment, 97% of patients receiving T-DM1 had no evidence of cancer recurrence. The rate of clinically relevant toxicities was similar in the T-DM1 group and the chemotherapy-and-trastuzumab group. However, patient-reported outcomes from this study shower better quality of life with T-DM1, that was associated with less neuropathy, less hair loss and better work productivity than chemotherapy and trastuzumab.

HER2DX testing showed that patients with a risk score above an established threshold had a significantly higher chance of cancer recurrence.

“The ATEMPT trial has taught us that one year of T-DM1 after surgery for patients with a stage 1 HER2-positive cancer leads to outstanding long term outcomes, making it a reasonable treatment approach for select patients,” says senior author Sara Tolaney, MD, MPH, Chief, Division of Breast Oncology, Dana-Farber Cancer Institute.

Genentech, Gloria Spivak Faculty Advancement Fund, and Susan G. Komen supported the trial.

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Copy Link
Share
Previous Article Danaher names Julie Sawyer Montgomery Executive VP for Diagnostics Danaher appoints Julie Sawyer Montgomery as Executive Vice President for Diagnostics
Next Article Latest: AbbVie Acquires Celsius Therapeutics Latest: AbbVie Acquires Celsius Therapeutics

Recent Posts

  • The View Hospital Becomes Qatar’s First to Earn JCI 8th Edition Accreditation
  • Aya Healthcare Names Emily Hazen as CEO
  • Why Some Babies Walk Sooner: New Study Finds Genetic Clues Behind Baby’s First Steps
  • Farabursen Joins Novartis Pipeline in $1.7B Regulus Deal Targeting ADPKD
  • Dimitris Moulavasilis Takes the Helm as M42 Group CEO
  • Dermatology expo rome
  • LifeSpin
Two Point Five Logo white
  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: Breakthrough! New Weapon Strikes Down Breast Cancer Recurrence
Share

Published by Two Point Five Media FZCO

  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: Breakthrough! New Weapon Strikes Down Breast Cancer Recurrence
Share

Follow US on Social Media

Facebook Instagram Linkedin X-twitter Youtube Whatsapp
Logo of Medede mea
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?